{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:20:15Z","timestamp":1773436815721,"version":"3.50.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/aci.0000000000000089","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T17:08:46Z","timestamp":1406048926000},"page":"457-463","source":"Crossref","is-referenced-by-count":32,"title":["Topical immunomodulators in the management of allergic eye diseases"],"prefix":"10.1097","volume":"14","author":[{"given":"Nir","family":"Erdinest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0149-2918(00)80055-7","article-title":"A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1 ophthalmic solution and ketotifen fumarate 0.025 ophthalmic solution in the conjunctival antigen challenge model.","volume":"22","author":"Berdy","year":"2000","journal-title":"Clin Ther"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/msj.20291","article-title":"Ocular allergy.","volume":"78","author":"Bielory","year":"2011","journal-title":"Mt Sinai J Med"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.iac.2007.12.001","article-title":"Ocular allergy treatment.","volume":"28","author":"Bielory","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ACI.0b013e3282ef868b","article-title":"Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review.","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R5-13-20210128","first-page":"1603","article-title":"Omalizumab: a future innovation for treatment of severe ocular allergy Expert Opin Biol T","volume":"5","author":"Williams","year":"2005","journal-title":"her"},{"key":"R6-13-20210128","first-page":"485","article-title":"Ocular allergy: diagnosis and treatment.","volume":"18","author":"Butrus","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14656561003694643","article-title":"Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.","volume":"11","author":"Leonardi","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1365-2222.2007.02782.x","article-title":"Ocular antiallergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.","volume":"37","author":"Galatowicz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00417-002-0612-6","article-title":"Preservative-free diclofenac sodium 0.1 for vernal keratoconjunctivitis.","volume":"241","author":"DAngelo","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","article-title":"Corticosteroid-induced cataracts.","volume":"31","author":"Urban","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/jir.2005.25.604","article-title":"Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.","volume":"25","author":"Payvandi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-3164.2004.00376.x","article-title":"Cyclosporin A: a new drug in the field of canine dermatology.","volume":"15","author":"Guaguere","year":"2004","journal-title":"Vet Dermatol"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine.","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000053836","article-title":"Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis.","volume":"125","author":"Bunikowski","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.4049\/jimmunol.144.10.3891","article-title":"Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.","volume":"144","author":"Cirillo","year":"1990","journal-title":"J Immunol"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/thx.52.5.447","article-title":"Effect of cyclosporin A on the allergen-induced late asthmatic reaction.","volume":"52","author":"Sihra","year":"1997","journal-title":"Thorax"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0165-2427(01)00315-4","article-title":"The ACVD Task Force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy.","volume":"81","author":"Marsella","year":"2001","journal-title":"Vet Immunol Immunopathol"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1610-0387.2008.06834.x","article-title":"Systemic therapeutic options for severe atopic dermatitis.","volume":"7","author":"BuBmann","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-3164.2006.00511.x","article-title":"Dermal microdialysis in the dog: in vivo assessment of the effect of cyclosporin A on cutaneous histamine and prostaglandin D2 release.","volume":"17","author":"Brazis","year":"2006","journal-title":"Vet Dermatol"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2133.1997.6081584.x","article-title":"Cyclosporin inhibits intercellular adhesion molecule-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation.","volume":"136","author":"Oran","year":"1997","journal-title":"Br J Dermatol"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V86.7.2689.2689","article-title":"Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT.","volume":"86","author":"Cockerill","year":"1995","journal-title":"Blood"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.biotechadv.2011.03.004","article-title":"Cyclosporin A - a review on fermentative production, downstream processing and pharmacological applications.","volume":"29","author":"Survase","year":"2011","journal-title":"Biotechnol Adv"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A.","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis.","volume":"101","author":"BenEzra","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":"A large prospective observational study of novel cyclosporine 0.1 aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.","volume":"25","author":"Ebihara","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":"A randomized trial of topical cyclosporin 0.05 in topical steroid-resistant atopic keratoconjunctivitis.","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10384-008-0577-z","article-title":"Efficacy of topical cyclosporin A 0.05 in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children.","volume":"52","author":"Keklikci","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","article-title":"Management of severe allergic conjunctivitis with topical cyclosporin a 0.05 eyedrops.","volume":"26","author":"Ozcan","year":"2007","journal-title":"Cornea"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":"Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R32-13-20210128","first-page":"190","article-title":"Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis.","volume":"87","author":"Kosrirukvongs","year":"2004","journal-title":"J Med Assoc Thai"},{"key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","article-title":"Efficacy of 1.25 and 1 topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood.","volume":"17","author":"Spadavecchia","year":"2006","journal-title":"Pediatr Allergy Immunol"},{"issue":"Pt 1","key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis.","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye (Lond)"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","article-title":"Topical cyclosporine in vernal keratoconjunctivitis.","volume":"98","author":"Bleik","year":"1991","journal-title":"Ophthalmology"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":"Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","article-title":"Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial.","volume":"96","author":"De Smedt","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.139.6.1797","article-title":"Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.","volume":"139","author":"Sawada","year":"1987","journal-title":"J Immunol"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/petr.12056","article-title":"Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review.","volume":"17","author":"Gijsen","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2007.08177.x","article-title":"The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.","volume":"157","author":"Rustin","year":"2007","journal-title":"Br J Dermatol"},{"key":"R45-13-20210128","first-page":"270","article-title":"Tacrolimus in pediatric renal transplantation: a review.","volume":"2","author":"Shapiro","year":"1998","journal-title":"Pediatr Transplant"},{"key":"R46-13-20210128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-0012.1998.tb01004.x","article-title":"The role of tacrolimus in adult kidney transplantation: a review.","volume":"12","author":"Laskow","year":"1998","journal-title":"Clin Transplant"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/106002809402800414","article-title":"Tacrolimus, a new immunosuppressant: a review of the literature.","volume":"28","author":"Hooks","year":"1994","journal-title":"Ann Pharmacother"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1540-9740.2007.06485.x","article-title":"Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I.","volume":"7","author":"Sehgal","year":"2008","journal-title":"Skinmed"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(99)00500-2","article-title":"Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models.","volume":"379","author":"Sengoku","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2165\/00003495-199346040-00009","article-title":"A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.","volume":"46","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005 tacrolimus eye drop for refractory vernal keratoconjunctivitis.","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye (Lond)"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease.","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R53-13-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-0420.2006.00699.x","article-title":"Effect of 0.03 tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study.","volume":"84","author":"Virtanen","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R54-13-20210128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/bjo.2009.172387","article-title":"Topical tacrolimus 0.03 monotherapy for vernal keratoconjunctivitis: case series.","volume":"94","author":"Tam","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R55-13-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":"Topical tacrolimus 0.03 ointment for intractable allergic conjunctivitis: an open-label pilot study.","volume":"33","author":"Attas-Fox","year":"2008","journal-title":"Curr Eye Res"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":"Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids.","volume":"23","author":"Zribi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":"Tacrolimus ointment 0.03 in the eye for treatment of giant papillary conjunctivitis.","volume":"27","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"key":"R58-13-20210128","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"R59-13-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 in severe allergic conjunctivitis.","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R60-13-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":"Vernal keratoconjunctivitis: result of a novel therapy with 0.1 topical ophthalmic FK-506 ointment.","volume":"113","author":"Vichyanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R61-13-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajo.2013.10.006","article-title":"Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.","volume":"157","author":"Al-Amri","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R62-13-20210128","first-page":"378","article-title":"Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1 tacrolimus treatment.","volume":"118","author":"Harada","year":"2014","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"R63-13-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2332\/allergolint.11-OA-0349","article-title":"Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1 tacrolimus ophthalmic suspension.","volume":"61","author":"Ebihara","year":"2012","journal-title":"Allergol Int"},{"key":"R64-13-20210128","first-page":"177","article-title":"A double-masked comparison of 0.1 tacrolimus ointment and 2 cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R65-13-20210128","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2005.10.008","article-title":"In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.","volume":"110","author":"Forrest","year":"2006","journal-title":"J Control Release"},{"key":"R66-13-20210128","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E","article-title":"Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis.","volume":"30","author":"Magone","year":"2000","journal-title":"Eur J Immunol"},{"key":"R67-13-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2004.10.042","article-title":"Allergic conjunctivitis: update on pathophysiology and prospects for future treatment.","volume":"115","author":"Ono","year":"2005","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:17:39Z","timestamp":1746310659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201410000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000089","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}